医学
生物人工肝装置
荟萃分析
随机对照试验
协议(科学)
梅德林
贝叶斯网络
肝衰竭
排名(信息检索)
肝移植
内科学
重症监护医学
外科
移植
人工智能
计算机科学
病理
替代医学
体外
生物化学
法学
政治学
肝细胞
化学
作者
Klementina Ocskay,Anna Kanjo,Noémi Gede,Zsolt Szakács,Gabriella Pár,Bálint Mihály Erőss,Jan Stange,Steffen R Mitzner,Péter Hegyi,Zsolt Molnár
标识
DOI:10.1186/s13613-020-00795-0
摘要
BACKGROUND: The role of artificial and bioartificial liver support systems in acute-on-chronic liver failure (ACLF) is still controversial. We aimed to perform the first network meta-analysis comparing and ranking different liver support systems and standard medical therapy (SMT) in patients with ACLF. METHODS: The study protocol was registered with PROSPERO (CRD42020155850). A systematic search was conducted in five databases. We conducted a Bayesian network meta-analysis of randomized controlled trials assessing the effect of artificial or bioartificial liver support systems on survival in patients with ACLF. Ranking was performed by calculating the surface under cumulative ranking (SUCRA) curve values. The RoB2 tool and a modified GRADE approach were used for the assessment of the risk of bias and quality of evidence (QE). RESULTS: In the quantitative synthesis 16 trials were included, using MARS®, Prometheus®, ELAD®, plasma exchange (PE) and BioLogic-DT®. Overall (OS) and transplant-free (TFS) survival were assessed at 1 and 3 months. PE significantly improved 3-month OS compared to SMT (RR 0.74, CrI: 0.6-0.94) and ranked first on the cumulative ranking curves for both OS outcomes (SUCRA: 86% at 3 months; 77% at 1 month) and 3-month TFS (SUCRA: 87%) and second after ELAD for 1-month TFS (SUCRA: 76%). Other comparisons did not reach statistical significance. QE was moderate for PE concerning 1-month OS and both TFS outcomes. Other results were of very low certainty. CONCLUSION: PE seems to be the best currently available liver support therapy in ACLF regarding 3-month OS. Based on the low QE, randomized trials are needed to confirm our findings for already existing options and to introduce new devices.
科研通智能强力驱动
Strongly Powered by AbleSci AI